OMass secures new funds

Wednesday 18 May 2022

United Kingdom

OMass Therapeutics Ltd, a 2016 spin-out from the University of Oxford, has raised $100 million in a Series B financing round to advance its pipeline of drugs for immunology disorders and rare diseases. Proceeds from the financing will advance the company’s small molecule therapeutics towards clinical trials. The pipeline includes drugs targeting solute carriers, a group of membrane transport proteins, and G-protein coupled receptors (GPCRs), a diverse group of cell surface receptors.